GlassScriptPhysician profile
Warren L Dinges
NPI 1194832667
$172,837.75
in general payments reported to CMS, 2019-2025
9 companies · $33K in 2025
The $33K reported for 2025 was more than what 97% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $11K · 2021: $6,354 · 2022: $15K · 2023: $33K · 2024: $39K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Travel and Lodging: $19K · Consulting Fee: $5,722 · Food and Beverage: $5,201 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,288.00 |
| Travel and Lodging | $18,827.72 |
| Consulting Fee | $5,721.67 |
| Food and Beverage | $5,201.35 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $169,772.00 | 2019-2025 | Descovy, Biktarvy, Yeztugo |
| Viiv Healthcare Company | $1,329.94 | 2019-2023 | Apretude, Dovato, Cabenuva |
| Theratechnologies INC. | $875.44 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $361.67 | 2023 | |
| Merck Sharp & Dohme LLC | $173.66 | 2019-2023 | Delstrigo |
| Janssen Biotech, INC. | $138.94 | 2020-2023 | Prezcobix |
| Abbott Laboratories | $100.00 | 2019 | |
| Emd Serono, INC. | $51.25 | 2019-2021 | |
| Fisher Scientific Company L.L.C. | $34.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Dinges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.